Paper38374366
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M and 2 others. Eye (Lond), 2024. Cited by 52 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Papers, record 38374366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38374366
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.
- PubMed
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Graves Ophthalmopathy | Major topic |
| Humans | |
| Antibodies, Monoclonal, Humanized |
Source PubMed
References144
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35227694 | Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. | Am J Ophthalmol | 2022 | https://conductscience.org/library/papers/35227694 | PubMed |
| 2 | 31354709 | The Neonatal Fc Receptor (FcRn): A Misnomer? | Front Immunol | 2019 | https://conductscience.org/library/papers/31354709 | PubMed |
| 3 | 10720061 | Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. | J Clin Endocrinol Metab | 2000 | https://conductscience.org/library/papers/10720061 | PubMed |
| 4 | 15998777 | Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. | J Clin Endocrinol Metab | 2005 | https://conductscience.org/library/papers/15998777 | PubMed |
| 5 | 29396246 | Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. | Lancet Diabetes Endocrinol | 2018 | https://conductscience.org/library/papers/29396246 | PubMed |
| 6 | 35604323 | Current concepts regarding Graves' orbitopathy. | J Intern Med | 2022 | https://conductscience.org/library/papers/35604323 | PubMed |
| 7 | 32107168 | Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. | Best Pract Res Clin Endocrinol Metab | 2020 | https://conductscience.org/library/papers/32107168 | PubMed |
| 8 | 33511081 | Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy. | Eur Thyroid J | 2020 | https://conductscience.org/library/papers/33511081 | PubMed |
| 9 | 18786258 | Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. | Arthritis Res Ther | 2008 | https://conductscience.org/library/papers/18786258 | PubMed |
| 10 | 36683389 | Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study. | J Clin Endocrinol Metab | 2023 | https://conductscience.org/library/papers/36683389 | PubMed |
| 11 | 35709102 | Rituximab for thyroid-associated ophthalmopathy. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/35709102 | PubMed |
| 12 | 12794168 | Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. | J Immunol | 2003 | https://conductscience.org/library/papers/12794168 | PubMed |
| 13 | 24916606 | Methotrexate for treating rheumatoid arthritis. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/24916606 | PubMed |
| 14 | 19221109 | Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. | Br J Ophthalmol | 2009 | https://conductscience.org/library/papers/19221109 | PubMed |
| 15 | 9530102 | Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. | Am J Physiol | 1998 | https://conductscience.org/library/papers/9530102 | PubMed |
| 16 | 27760790 | MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. | Eur J Endocrinol | 2017 | https://conductscience.org/library/papers/27760790 | PubMed |
| 17 | 2519530 | Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. | N Engl J Med | 1989 | https://conductscience.org/library/papers/2519530 | PubMed |
| 18 | 33783712 | Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. | Hormones (Athens) | 2021 | https://conductscience.org/library/papers/33783712 | PubMed |
| 19 | 24783001 | Oxidative stress in graves' disease. | Eur Thyroid J | 2012 | https://conductscience.org/library/papers/24783001 | PubMed |
| 20 | 21591944 | Selenium and the course of mild Graves' orbitopathy. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21591944 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941257 | Systemic Inflammatory Markers, Thyroid Autoimmunity, and Neuroretinal Structure in Graves' Disease: A Comparative OCT Study According to Ophthalmopathy Status. | Metabolites | 2026 | https://conductscience.org/library/papers/42941257 | PubMed |
| 42787010 | Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42787010 | PubMed |
| 42766069 | Quantitative evaluation of synthetic MRI for assessing disease activity in thyroid eye disease. | Eur Radiol Exp | 2026 | https://conductscience.org/library/papers/42766069 | PubMed |
| 42741468 | How to manage thyroid eye disease: recent advances - a narrative review. | Drugs Context | 2026 | https://conductscience.org/library/papers/42741468 | PubMed |
| 42671097 | Efficacy and safety of secondary infero-medial orbital wall decompression after orbital fat decompression in Graves' orbitopathy: A 12-year experience. | Indian J Ophthalmol | 2026 | https://conductscience.org/library/papers/42671097 | PubMed |
| 42518709 | Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database. | Clin Ophthalmol | 2026 | https://conductscience.org/library/papers/42518709 | PubMed |
| 42455407 | Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study. | Endocrine | 2026 | https://conductscience.org/library/papers/42455407 | PubMed |
| 41697457 | The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease. | Rev Endocr Metab Disord | 2026 | https://conductscience.org/library/papers/41697457 | PubMed |
| 41675362 | Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization. | Laryngoscope Investig Otolaryngol | 2026 | https://conductscience.org/library/papers/41675362 | PubMed |
| 41533941 | Transcriptomic Profiling of Orbital Fat Tissue and Ocular Surface Wash in Active Thyroid Eye Disease Requiring Urgent Orbital Decompression. | Invest Ophthalmol Vis Sci | 2025 | https://conductscience.org/library/papers/41533941 | PubMed |
| 41509944 | Clinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study. | Turk J Med Sci | 2025 | https://conductscience.org/library/papers/41509944 | PubMed |
| 41495351 | Enhancing ocular sign detection: AI-based strategic segmentation for improved accuracy and privacy protection. | NPJ Digit Med | 2026 | https://conductscience.org/library/papers/41495351 | PubMed |
| 41462485 | Modulation of gut microbiota in Graves' orbitopathy: Prevotella dominance and atorvastatin's impact. | Microbiome | 2025 | https://conductscience.org/library/papers/41462485 | PubMed |
| 41322343 | Evaluation of clinical and ocular surface changes in thyroid eye disease: impact of treatment and risk factors. | Ther Adv Ophthalmol | 2025 | https://conductscience.org/library/papers/41322343 | PubMed |
| 41316028 | Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy. | BMC Med Imaging | 2025 | https://conductscience.org/library/papers/41316028 | PubMed |
| 41246121 | Advancing the Therapeutic Frontier in Thyroid Eye Disease. | touchREV Endocrinol | 2025 | https://conductscience.org/library/papers/41246121 | PubMed |
| 41180578 | The role of mycophenolate mofetil in the therapy of thyroid eye disease. | Ther Adv Endocrinol Metab | 2025 | https://conductscience.org/library/papers/41180578 | PubMed |
| 40834360 | Exploring thyroid eye disease in Brazil: insights from a single-center study. | Arch Endocrinol Metab | 2025 | https://conductscience.org/library/papers/40834360 | PubMed |
| 40807149 | Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies. | J Clin Med | 2025 | https://conductscience.org/library/papers/40807149 | PubMed |
| 40787463 | Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions. | Front Immunol | 2025 | https://conductscience.org/library/papers/40787463 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38374366
GET https://conductscience.org/api/papers/v1/38374366/references?page=2